Category: Prescription Drugs
Global Prescription Drugs
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of ... Read More
-
Tuberculosis Therapeutics
... CAGR of 2.7% over the analysis period 2024-2030. Active TB Therapeutics, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end of the ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Herpes Simplex Virus Infections
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR The Herpes Simplex Virus Infections market ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Isosorbide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
... forecast period 2024-2030. North American market for Isosorbide was valued at $ 30.30 million in 2023 and will reach $ 68.92 million by 2030, at a CAGR of 13.55% during the forecast period of 2024 ... Read More
-
Global Ursodeoxycholic Acid API Market Report, History and Forecast 2020-2031
... of 9.05% during the forecast period 2025-2031. North American market for Ursodeoxycholic Acid API was valued at $ 95.37 million in 2024, will reach $ 170.82 million by 2031, at a CAGR of 8.91% during ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative APIs, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Swine Health
... CAGR of 5.8% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$2.5 Billion by the end of the analysis period. ... Read More
-
Stroke Management
... CAGR of 5.3% over the analysis period 2024-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$35.9 Billion by the end of the analysis ... Read More
-
Emergency Contraceptive Pills
... at a CAGR of 2.4% over the analysis period 2024-2030. Combination Pills, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$484.2 Million by the end of ... Read More
-
Antipsychotic Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$15.7 Billion by the end of ... Read More
-
Potassium Bromide
... CAGR of 4.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.5 Million While China is Forecast to Grow at 7.8% CAGR The Potassium Bromide market in the U.S. is estimated at ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the ... Read More
-
Anti-Hypertensive Drugs
... CAGR of 2.7% over the analysis period 2024-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Sleeping Aids
... CAGR of 5.3% over the analysis period 2024-2030. Sleep Apnea Devices, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$36.9 Billion by the end of the ... Read More
-
Antidepressants
... 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More
-
Statins
... 1.8% over the analysis period 2024-2030. Synthetic Statins, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
Research Assistance
